Percheron Therapeutics (ASX:PER) has ended its American Depository Receipt (ADR) facility with financial services provider BNY Mellon, according to a Tuesday filing with the Australian bourse.
The ADR, trading with the ticker 'ATHJY' will no longer be quoted via over-the-counter (OTC) markets, the filing said.
The biotechnology company has now uplisted its foreign shares (F shares), trading with the ticker 'ATHJF', to the Over-the-Counter Bulletin Board (OTCQB) tier of the OTC markets.
The company has applied to the US Financial Industry Regulatory Authority for sponsorship of its F shares and a ticker change from 'ATHJF' to 'PERCF.'
These moves are expected to improve access to the company's securities to US investors and reduce costs for the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。